Multiple factors, including genetic and epigenetic fluctuations, have been linked to gastric cancer formation and progression. Cytosine methylation (5mC) has been recognized as a critical epigenetic mark in the mammalian genome. The recent discovery of 5-hydroxymethylcytosine (5hmC), which is generated by ten-eleven translocation (TET) enzymes, provides new perspectives to understand DNA methylation-related plasticity. In this study, we show that gastric tumors display significant loss of 5hmC. Using matched distant normal, peripheral, and tumor primary tissues, we performed genome-wide profiling of 5hmC and identified differentially hydroxymethylated regions (DhMRs) specifically associated with gastric tumors. Gene ontology analyses indicated that DhMRs (both loss of 5hmC and gain of 5hmC) were enriched among the genes involved in specific pathways. Interestingly, the binding motif of hypoxia-inducible factor 1 (HIF1) is enriched among both peripheral and tumor DhMRs, while the Myc-binding motif is specifically enriched among only tumor DhMRs. Tumor progression analyses revealed a unique set of DhMRs that correlate with tumor progression. These data together suggest that alteration of 5hmC could potentially contribute to the tumorigenesis of gastric tumors.
ChengY., BernsteinA., ChenD., and JinP. (2015). 5-hydroxymethylcytosine: a new player in brain disorders?. Exp Neurol, 268, 3–9.
3.
ConsortiumE.P. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature, 489, 57–74.
4.
CortazarD., KunzC., SelfridgeJ., LettieriT., SaitoY., MacDougallE., et al. (2011). Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability. Nature, 470, 419–423.
5.
CortellinoS., XuJ., SannaiM., MooreR., CarettiE., CiglianoA., et al. (2011). Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell, 146, 67–79.
6.
DaviesH., BignellG.R., CoxC., StephensP., EdkinsS., CleggS., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949–954.
7.
DawlatyM.M., GanzK., PowellB.E., HuY.C., MarkoulakiS., ChengA.W., et al. (2011). Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell, 9, 166–175.
8.
DoegeC.A., InoueK., YamashitaT., RheeD.B., TravisS., FujitaR., et al. (2012). Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature, 488, 652–655.
9.
EggerG., LiangG., AparicioA., and JonesP.A. (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature, 429, 457–463.
10.
FeinbergA.P., and TyckoB. (2004). The history of cancer epigenetics. Nat Rev Cancer, 4, 143–153.
11.
FeinbergA.P., and VogelsteinB. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 301, 89–92.
12.
FerlayJ., SoerjomataramI., DikshitR., EserS., MathersC., RebeloM., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, E359–E386.
13.
GuT.P., GuoF., YangH., WuH.P., XuG.F., LiuW., et al. (2011). The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature, 477, 606–610.
14.
HaffnerM.C., ChauxA., MeekerA.K., EsopiD.M., GerberJ., PellakuruL.G., et al. (2011). Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget, 2, 627–637.
15.
HeY.F., LiB.Z., LiZ., LiuP., WangY., TangQ., et al. (2011). Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science, 333, 1303–1307.
16.
Huang daW., ShermanB.T., and LempickiR.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4, 44–57.
17.
ItoS., D'AlessioA.C., TaranovaO.V., HongK., SowersL.C., and ZhangY. (2010). Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature, 466, 1129–1133.
18.
ItoS., ShenL., DaiQ., WuS.C., CollinsL.B., SwenbergJ.A., et al. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science, 333, 1300–1303.
19.
JaenischR., and BirdA. (2003). Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet, 33Suppl, 245–254.
20.
JinS.G., JiangY., QiuR., RauchT.A., WangY., SchackertG., et al. (2011). 5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res, 71, 7360–7365.
21.
JonesP.A., and BaylinS.B. (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet, 3, 415–428.
22.
KellerG., GrimmV., VogelsangH., BischoffP., MuellerJ., SiewertJ.R., et al. (1996). Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. Int J Cancer, 68, 571–576.
23.
KoM., HuangY., JankowskaA.M., PapeU.J., TahilianiM., BandukwalaH.S., et al. (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 468, 839–843.
24.
KohK.P., YabuuchiA., RaoS., HuangY., CunniffK., NardoneJ., et al. (2011). Tet1 and tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell, 8, 200–213.
25.
KriaucionisS., and HeintzN. (2009). The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science, 324, 929–930.
26.
KulisM., and EstellerM. (2010). DNA methylation and cancer. Adv Genet, 70, 27–56.
27.
LianC.G., XuY., CeolC., WuF., LarsonA., DresserK., et al. (2012). Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell, 150, 1135–1146.
28.
LiuC., LiuL., ChenX., ShenJ., ShanJ., XuY., et al. (2013). Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One, 8, e62828.
29.
MaitiA., and DrohatA.C. (2011). Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem, 286, 35334–35338.
30.
Moran-CrusioK., ReavieL., ShihA., Abdel-WahabO., Ndiaye-LobryD., LobryC., et al. (2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell, 20, 11–24.
31.
MurataniM., DengN., OoiW.F., LinS.J., XingM., XuC., et al. (2014). Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nat Commun, 5, 4361.
PadmanabhanN., UshijimaT., and TanP. (2017). How to stomach an epigenetic insult: the gastric cancer epigenome. Nat Rev Gastroenterol Hepatol, 14, 467–478.
34.
PfaffenederT., HacknerB., TrussM., MunzelM., MullerM., DeimlC.A., et al. (2011). The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem Int Ed Engl, 50, 7008–7012.
35.
QamraA., XingM., PadmanabhanN., KwokJ.J.T., ZhangS., XuC., et al. (2017). Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma. Cancer Discov, 7, 630–651.
36.
ShimY.H., KangG.H., and RoJ.Y. (2000). Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest, 80, 689–695.
37.
SongC.X., SzulwachK.E., FuY., DaiQ., YiC., LiX., et al. (2011). Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol, 29, 68–72.
38.
SpruijtC.G., GnerlichF., SmitsA.H., PfaffenederT., JansenP.W., BauerC., et al. (2013). Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell, 152, 1146–1159.
39.
SzulwachK.E., LiX., LiY., SongC.X., WuH., DaiQ., et al. (2011). 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci, 14, 1607–1616.
40.
TahilianiM., KohK.P., ShenY., PastorW.A., BandukwalaH., BrudnoY., et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 324, 930–935.
41.
TanL., and ShiY.G. (2012). Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development, 139, 1895–1902.
42.
TanP., and YeohK.G. (2015). Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology, 149, 1153–1162. e3.
43.
WangT., WuH., LiY., SzulwachK.E., LinL., LiX., et al. (2013). Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency. Nat Cell Biol, 15, 700–711.
44.
WilliamsK., ChristensenJ., PedersenM.T., JohansenJ.V., CloosP.A., RappsilberJ., et al. (2011). TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature, 473, 343–348.
45.
XuY., WuF., TanL., KongL., XiongL., DengJ., et al. (2011). Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell, 42, 451–464.
46.
YangF., BiJ., XueX., ZhengL., ZhiK., HuaJ., et al. (2012). Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J, 279, 3159–3165.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
